Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Thiogenesis Therapeutics Corp ( (TSE:TTI) ) has shared an announcement.
Thiogenesis Therapeutics Corp announced the FDA clearance of its Investigational New Drug application for TTI-0102, aimed at treating Leigh syndrome spectrum, a rare pediatric mitochondrial disease. The clearance allows the company to initiate a Phase 2a clinical trial in collaboration with the Children’s Hospital of Philadelphia, marking a significant milestone in their efforts to address unmet medical needs in mitochondrial diseases. The trial will assess the safety and efficacy of TTI-0102, which has the potential to enhance intracellular glutathione levels and improve patient outcomes.
More about Thiogenesis Therapeutics Corp
Thiogenesis Therapeutics Corp is a clinical-stage biotechnology company focused on developing disulfides that enhance the production of intracellular cysteine, a precursor to critical antioxidants like glutathione. The company is positioned in the biotechnology industry with a focus on addressing rare genetic diseases, particularly those involving mitochondrial dysfunction.
Average Trading Volume: 34,433
Technical Sentiment Signal: Buy
Current Market Cap: C$32.41M
See more insights into TTI stock on TipRanks’ Stock Analysis page.